Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Gains from Investment Securities (2020 - 2023)

Caribou Biosciences (CRBU) has disclosed Gains from Investment Securities for 4 consecutive years, with $170000.0 as the latest value for Q2 2023.

  • On a quarterly basis, Gains from Investment Securities fell 97.43% to $170000.0 in Q2 2023 year-over-year; TTM through Sep 2024 was $170000.0, a 0.0% change, with the full-year FY2025 number at $2.1 million, changed N/A from a year prior.
  • Gains from Investment Securities was $170000.0 for Q2 2023 at Caribou Biosciences, down from $6.6 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $6.6 million in Q2 2022 to a low of $10000.0 in Q4 2020.
  • A 4-year average of $1.5 million and a median of $170000.0 in 2023 define the central range for Gains from Investment Securities.
  • Biggest YoY gain for Gains from Investment Securities was 97.43% in 2023; the steepest drop was 97.43% in 2023.
  • Caribou Biosciences' Gains from Investment Securities stood at $10000.0 in 2020, then surged by 1090.0% to $119000.0 in 2021, then skyrocketed by 5455.43% to $6.6 million in 2022, then crashed by 97.43% to $170000.0 in 2023.
  • Per Business Quant, the three most recent readings for CRBU's Gains from Investment Securities are $170000.0 (Q2 2023), $6.6 million (Q2 2022), and $420224.0 (Q1 2022).